See more : Gokaldas Exports Limited (GOKEX.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Merrimack Pharmaceuticals, Inc. (MACK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Merrimack Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nasdaq, Inc. (0K4T.L) Income Statement Analysis – Financial Results
- Tomita Co., Ltd. (8147.T) Income Statement Analysis – Financial Results
- Merkur PrivatBank KgaA (MBK.DE) Income Statement Analysis – Financial Results
- Safran SA (SAF.PA) Income Statement Analysis – Financial Results
- Parnax Lab Limited (PARNAXLAB.BO) Income Statement Analysis – Financial Results
Merrimack Pharmaceuticals, Inc. (MACK)
About Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 144.27M | 89.26M | 102.76M | 47.79M | 48.92M | 34.22M | 20.31M | 2.15M |
| Cost of Revenue | 0.00 | 445.00K | 0.00 | 0.00 | 2.23M | 0.00 | 0.00 | 6.91M | 46.00K | 0.00 | 0.00 | 0.00 | 100.63M | 58.28M | 37.66M |
| Gross Profit | 0.00 | -445.00K | 0.00 | 0.00 | -2.23M | 0.00 | 0.00 | 137.36M | 89.21M | 102.76M | 47.79M | 48.92M | -66.42M | -37.97M | -35.51M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 95.21% | 99.95% | 100.00% | 100.00% | 100.00% | -194.11% | -187.01% | -1,653.17% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 11.10M | 49.97M | 67.31M | 160.92M | 160.99M | 138.50M | 147.14M | 125.86M | 365.00K | 0.00 | 0.00 |
| General & Administrative | 2.18M | 2.17M | 2.62M | 5.01M | 16.17M | 15.60M | 28.45M | 0.00 | 0.00 | 30.52M | 21.19M | 15.81M | 8.84M | 0.00 | 0.00 |
| Selling & Marketing | 2.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.62M | 0.00 | 0.00 |
| SG&A | 2.18M | 2.17M | 2.62M | 5.01M | 16.17M | 15.60M | 28.45M | 80.73M | 57.60M | 30.52M | 21.19M | 15.81M | 14.45M | 11.38M | 12.18M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -191.00K | 370.00K | -3.23M | -1.43M | -43.38M | -18.22M | -17.30M | -10.15M | 988.00K | 34.16M | 0.00 | 0.00 |
| Operating Expenses | 2.18M | 2.17M | 2.62M | 5.01M | 27.27M | 65.58M | 95.77M | 241.65M | 218.58M | 169.01M | 168.33M | 141.66M | 14.45M | 11.38M | 12.18M |
| Cost & Expenses | 2.18M | 2.17M | 2.62M | 5.01M | 27.27M | 65.58M | 95.77M | 248.56M | 218.63M | 169.01M | 168.33M | 141.66M | 115.08M | 69.66M | 49.84M |
| Interest Income | 868.00K | 188.00K | 20.00K | 50.00K | 777.00K | 1.30M | 895.00K | 276.00K | 99.00K | 114.00K | 166.00K | 184.00K | 56.00K | 74.00K | 81.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 1.53M | 956.00K | 34.65M | 43.65M | 19.23M | 18.23M | 10.94M | 553.00K | 13.00K | 3.73M | 4.91M |
| Depreciation & Amortization | 167.90K | -890.00K | -288.00K | -2.28M | -1.54M | 4.07M | 5.22M | 6.25M | 4.29M | 3.22M | 2.59M | 3.66M | 5.33M | 4.38M | 2.76M |
| EBITDA | -2.18M | -2.62M | -2.76M | -5.15M | -20.26M | -65.58M | -91.08M | -110.14M | -125.28M | -66.26M | -120.54M | -92.74M | -75.49M | -44.90M | -44.85M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -68.22% | -144.94% | -64.48% | -252.25% | -189.58% | -220.63% | -221.13% | -2,088.08% |
| Operating Income | -2.18M | -1.73M | -2.47M | -2.87M | -22.36M | -65.58M | -95.77M | -110.14M | -129.57M | -66.26M | -120.54M | -92.74M | -80.87M | -49.18M | -47.69M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -76.34% | -145.16% | -64.48% | -252.25% | -189.58% | -236.36% | -242.19% | -2,220.11% |
| Total Other Income/Expenses | 1.01M | 188.00K | 20.00K | -141.00K | -381.00K | -2.89M | -22.64M | -43.38M | -18.22M | -17.30M | -10.15M | 1.47M | 1.19M | -983.00K | -4.79M |
| Income Before Tax | -1.17M | -1.54M | -2.45M | -3.01M | -22.74M | -68.46M | -118.40M | -153.52M | -147.79M | -83.56M | -130.69M | -91.75M | -79.68M | -50.16M | -52.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -106.41% | -165.57% | -81.32% | -273.48% | -187.56% | -232.87% | -247.03% | -2,442.97% |
| Income Tax Expense | 12.00K | 3.00K | 3.00K | 14.00K | -1.47M | -7.70M | -42.40M | -13.22M | -3.92M | -3.49M | -2.35M | -4.14M | -440.00K | 3.67M | -3.40M |
| Net Income | -1.18M | -1.54M | -2.46M | -3.03M | -21.27M | -40.51M | 472.03M | -151.74M | -147.96M | -83.29M | -130.93M | -91.28M | -79.22M | -50.10M | -49.07M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -105.18% | -165.76% | -81.06% | -273.98% | -186.58% | -231.54% | -246.76% | -2,284.59% |
| EPS | -0.08 | -0.11 | -0.18 | -0.23 | -1.59 | -3.04 | 35.67 | -12.11 | -13.29 | -7.98 | -13.24 | -12.53 | -8.57 | -44.17 | -43.26 |
| EPS Diluted | -0.08 | -0.11 | -0.18 | -0.23 | -1.59 | -3.04 | 35.67 | -12.11 | -13.29 | -7.98 | -13.24 | -12.53 | -8.57 | -44.17 | -43.26 |
| Weighted Avg Shares Out | 14.30M | 13.52M | 13.41M | 13.38M | 13.35M | 13.34M | 13.23M | 12.53M | 11.14M | 10.44M | 9.89M | 7.28M | 9.24M | 1.13M | 1.13M |
| Weighted Avg Shares Out (Dil) | 14.30M | 13.52M | 13.41M | 13.38M | 13.35M | 13.34M | 13.23M | 12.53M | 11.14M | 10.44M | 9.89M | 7.28M | 9.24M | 1.13M | 1.13M |
Seven Neal Gerber Eisenberg Attorneys Recognized for Excellence in Pro Bono Service
CHICAGO--(BUSINESS WIRE)--Neal Gerber Eisenberg (NGE) is pleased to announce that seven of its attorneys have received the 2023 Award for Excellence in Pro Bono Service from the U.S. District Court for the Northern District of Illinois and the Chicago Chapter...
Merrimack Reports First Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023. “During the first quarter of 2023 our operating expenses remained consistent with prior quarters...
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023
BERWYN, Pa.--(BUSINESS WIRE)--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced that Mr. Anthony P. Mack, Chairman...
CareFirst BlueCross BlueShield Reimagines Weight Management and Diabetes Prevention with Noom
NEW YORK--(BUSINESS WIRE)--Noom for Work, the commercial leader in behavior change, announced today that it would deliver two new preventive health solutions to commercial members of CareFirst BlueCross BlueShield’s (CareFirst): Noom Weight and Noom’s Diabetes Prevention Program. Beginning April 3,...
Claros Mortgage Trust, Inc. Reports First Quarter 2023 Results
NEW YORK--(BUSINESS WIRE)--Claros Mortgage Trust, Inc. (NYSE: CMTG) (the “Company” or “CMTG”) today reported its financial results for the quarter ended March 31, 2023. The Company’s first quarter 2023 GAAP net income was $36.7 million, or $0.26 per diluted share...
Wells Fargo Foundation Awards $7.5 Million to Habitat for Humanity to Build, Repair Homes
DES MOINES, Iowa--(BUSINESS WIRE)--Today, the Wells Fargo Foundation announced a $7.5 million grant to Habitat for Humanity International to help make homes more affordable and accessible for everyone. Through the 2023 Wells Fargo Builds program, the grant funding will enable...
Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™
BERWYN, Pa.--(BUSINESS WIRE)--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced that it has engaged Dr. Pardeep...
Merrimack Still Has Significant Arbitrage Potential
In December 2022, MACK got positive clinical results for its Phase III clinical trial of Onivyde in first line pancreatic cancer. A $225m milestone from Ipsen will be triggered on approval, which corresponds to about $16.75 per basic share.
Merrimack Pharmaceuticals (MACK) Stock Skyrockets Over 240%: Details
The stock price of Merrimack Pharmaceuticals (MACK) skyrocketed by over 240% today. This is why.
3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240%
Biotech penny stocks with upcoming events to watch in November 2022. The post 3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports